Table 4.

Linear Regression Analysis for Predictors of Left Ventricular Ejection Fraction in Lymphoma Survivors

	Univariable Analysis			Multivariable Model 1 (R2 = 0.183)			Multivariable Model 2 (R2 = 0.193)
	β	95% CI	P Value	β	95% CI	P Value	β	95% CI	P Value
Male	−1.71	−3.86 to 0.45	0.12	−1.48	−3.51 to 0.54	0.15	−1.45	−3.53 to 0.64	0.17
Age at CMR	−0.04	−0.14 to −0.06	0.40
Duration between diagnosis and CMR	−0.08	−0.21 to 0.05	0.20				0.005	−0.13 to 0.14	0.94
Body mass index	−0.19	−0.45 to 0.06	0.13	−0.08	−0.33 to 0.17	0.52	−0.09	−0.34 to 0.16	0.49
Heart rate	0.006	−0.09 to 0.10	0.91
Total mediastinal radiotherapy doses	−0.20	−0.40 to 0.00	0.050	−0.22	−0.43 to −0.01	0.023	−0.20	−0.41 to 0.03	0.053
High-dose anthracycline–containing chemotherapy	1.12	−1.88 to 4.21	0.45
Total dose anthracycline-containing chemotherapy	0.005	0.00 to 0.01	0.25				0.004	−0.01 to 0.01	0.35
Diabetes mellitus	−7.73	−13.21 to −2.26	0.006	−7.64	−13.20 to −2.08	0.008	−7.84	−13.52 to −2.17	0.007
Hyperlipidemia	1.96	−1.31 to 5.23	0.24
Hypertension	−0.09	−3.05 to 2.87	0.95
Hypothyroidism	0.50	−1.86 to 2.85	0.68
Hyperthyroidism	−0.84	−6.58 to 4.91	0.77
Current or former smoker	0.80	−1.55 to 3.15	0.50

All variables with P values <0.20 in the univariable linear regression were included in multivariable model 1. In multivariable model 2, the following variables irrespective of P value were added to the model: duration between diagnosis and CMR and total dose of anthracycline-containing chemotherapy.